Search research articles
Contact Us
Filters
Showing results (201-210 of 227) with videos related to
Page
of 23
Sort By:
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
Laurence Albiges, A Ari Hakimi, Wanling Xie, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 227) with videos related to
Sort By:
Page
of 23
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
The New England Journal of Medicine
|
March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer, Nizar M Tannir, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
Laurence Albiges, A Ari Hakimi, Wanling Xie, et al.
Page
of 23